US 12,076,410 B2
Nucleic acid carriers and therapeutic methods of use
Robert C. Getts, Hatfield, PA (US); James M. Kadushin, Hatfield, PA (US); and Lori Getts, Hatfield, PA (US)
Assigned to Code Biotherapeutics, Inc., Lower Gwynedd, PA (US)
Appl. No. 15/999,781
Filed by Code Biotherapeutics, Inc., Hatfield, PA (US)
PCT Filed Feb. 17, 2017, PCT No. PCT/US2017/018343
§ 371(c)(1), (2) Date Aug. 20, 2018,
PCT Pub. No. WO2017/143171, PCT Pub. Date Aug. 24, 2017.
Claims priority of provisional application 62/297,200, filed on Feb. 19, 2016.
Prior Publication US 2021/0162064 A1, Jun. 3, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 47/68 (2017.01); A61K 8/60 (2006.01); A61K 39/44 (2006.01); A61K 47/54 (2017.01); A61K 47/56 (2017.01)
CPC A61K 47/6881 (2017.08) [A61K 8/606 (2013.01); A61K 39/44 (2013.01); A61K 47/549 (2017.08); A61K 47/56 (2017.08); A61K 47/6807 (2017.08); A61K 47/6811 (2017.08); A61K 47/6849 (2017.08); A61K 47/6889 (2017.08)] 21 Claims
 
1. A single layer nucleic acid carrier comprising five monomers, wherein each monomer comprises:
a first and a second oligonucleotide;
wherein a central portion of each of the first and second oligonucleotides is complementary to each other, forming a double-stranded region,
wherein the double-stranded region formed by the complementary portions of the first and the second oligonucleotide is 25 to 35 bases in length,
wherein two terminal portions of the first oligonucleotide are not complementary to two terminal portions of the second oligonucleotide, thereby forming four terminal arms,
wherein the terminal portions of the first and the second oligonucleotide which are not complementary are each, independently, 25 to 35 bases in length,
wherein the first and the second oligonucleotide each, independently, further comprise one or two hinge segments joining one or both of the terminal arms to the double stranded region; and
wherein a first terminal arm of the first monomer is conjugated to a terminal arm of the second monomer, a second terminal arm of the first monomer is conjugated to a terminal arm of the third monomer, a third terminal arm of the first monomer is conjugated to a terminal arm of the fourth monomer, and a fourth terminal arm of the first monomer is conjugated to a terminal arm of the fifth monomer, forming a single layer nucleic acid carrier having twelve peripheral terminal arms.